Full Year 2024 Spirax Group PLC Earnings Call Transcript
Key Points
- Spirax Group PLC (SPXSY) achieved a full-year organic sales growth of 4%, outperforming the global industrial production (IP) growth of 1.7%.
- The ETS business showed strong performance with a 10% organic sales growth and a margin improvement to 16%, supported by a significant pipeline of customer inquiries for decarbonization-related electrification solutions.
- The company maintained a group margin of 20.1% through pricing discipline and efficiency savings, despite currency headwinds.
- Spirax Group PLC (SPXSY) increased its investment in future growth and achieved a higher cash conversion rate of 87%, supported by working capital improvement and lower capital expenditure.
- The company initiated a restructuring program aimed at simplifying the organization, which is expected to realize annualized savings of approximately GBP35 million, with 40% of this achieved in 2025.
- The STS business faced significant challenges in China, with organic sales growth of only 1% and a 13% decline in sales in China.
- Biopharm orders experienced a slower and more gradual recovery than expected, with sales growth below orders growth due to a low base.
- Currency movements negatively impacted sales by 5% and operating profit by 8%, affecting overall financial performance.
- The company anticipates continued challenges in China and Korea, impacting trading conditions and offsetting growth in other markets.
- The implementation of a new ERP system is expected to be a significant investment, potentially reaching a three-digit million cost, and may cause margin headwinds during the rollout.
Hello, and thanks for joining us for this presentation of Spirax Group's 2024 results. So I'm joined by Louisa Burdett today. And by now, you all know her well. Actually, this is the first set of results that Louisa is presenting as our CFO. And I'd like to start by acknowledging the hugely positive impact she's had on our group since she joined us last July.
So let me now summarize our 2024 performance. All three businesses delivered organic growth as well as margins in line with our expectations, and full-year group organic sales growth of 4% was well ahead of global IP of 1.7%. Growth was delivered against the backdrop of a challenging trading environment characterized by, firstly, third-party IP forecasts that were revised downwards throughout the year in light of shifting macroeconomic risks.
In particular, the second-half recovery that was forecast for IP did not materialize; secondly, a significant headwind to our STS business in China, which I highlighted at this time last year; thirdly, a slower and more gradual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
